drugsTreatmentPhase 2

HMBD-001

HMBD-001 is an experimental monoclonal antibody from Hummingbird Bioscience in phase 2 trials for non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer, aimed at HER3 and EGFR.

HMBD-001 is a monoclonal antibody developed by Hummingbird Bioscience. Its targets are HER3 and EGFR. ClinicalTrials.gov describes the intervention as: HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer, head and neck squamous cell carcinoma, oesophageal cancer, cervical cancer and cutaneous squamous cell carcinoma. The largest, NCT05910827, plans to enrol 398 participants with primary completion expected 2027-12-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.

How it works, step by step · animated schematic, not to scale; chosen from the modality "monoclonal antibody"

Monoclonal antibodies →

Modality

monoclonal antibody

Mechanism

Monoclonal antibody directed at HER3 and EGFR, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

HMBD-001

intervention: HMBD-001

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.